Search alternatives:
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
321
-
322
-
323
-
324
-
325
-
326
-
327
Longer <i>L</i><sub><i>h</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations of varying heminode length <i>L</i><sub><i>h</i></sub> at 70dB SPL, averaged over 50 simulations. …”
-
328
Longer <i>L</i><sub><i>u</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations with varying unmyelinated segment length <i>L</i><sub><i>u</i></sub> at 70dB SPL, averaged over 50 simulations. …”
-
329
-
330
DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx
Published 2022“…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”
-
331
-
332
-
333
-
334
-
335
-
336
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
337
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
338
-
339
-
340